UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000025083
Receipt number R000028848
Scientific Title A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris
Date of disclosure of the study information 2017/05/15
Last modified on 2023/12/07 23:00:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris

Acronym

A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris

Scientific Title

A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris

Scientific Title:Acronym

A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris

Region

Japan


Condition

Condition

psoriasis vulgaris

Classification by specialty

Dermatology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To find evidence of efficacy and safety of long term use of Dovobet ointment on patients with psoriasis vulgaris

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

comparison of m-PASI score at week 0, week 4, week24, and week52.

Key secondary outcomes

PGA and safety


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Age: 20 years old or over
2) Symptom: Manageable within 10g/day of Dovobet
3) Sex, inpatient/outpatient, does not matter

Key exclusion criteria

1) pregnant, or possibly pregnant women
2) subjects contraindicated by package insert
3) subjects judged unsuitable by physicians
4) subjects who are going to receive oral or injective steroid, cyclosporine, methotrexate, biologics, ultraviolet therapy, herbal medication against psoriasis within the trial period., 5) subjects who used Dovobet within 4 weeks before starting the trial.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Shinichi
Middle name
Last name Imafuku

Organization

Fukuoka University

Division name

Department of dermatology

Zip code

814-0180

Address

7-45-1, Nanakuma, Jonanku, Fukuoka city

TEL

092-801-1011

Email

dermatologist@mac.com


Public contact

Name of contact person

1st name Shinichi
Middle name
Last name Imafuku

Organization

Fukuoka University

Division name

Department of dermatology

Zip code

814-0180

Address

7-45-1, Nanakuma, Jonanku, Fukuoka city

TEL

092-801-1011

Homepage URL


Email

dermatologist@mac.com


Sponsor or person

Institute

Fukuoka University

Institute

Department

Personal name

Shinichi Imafuku


Funding Source

Organization

Fukuoka University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Internal Review Board, Fukuoka University

Address

7-45-1, Nanakkuma, Jonan-ku, Fukuoka City, Fukuoka Prefecture

Tel

092-801-1011

Email

dermatol@fukuoka-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 03 Month 20 Day

Date of IRB

2015 Year 05 Month 15 Day

Anticipated trial start date

2015 Year 06 Month 10 Day

Last follow-up date

2016 Year 05 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Observation of daily treated, or weekend treated, or calcipqotriol treated patients.


Management information

Registered date

2016 Year 11 Month 30 Day

Last modified on

2023 Year 12 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028848


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name